Abbott Laboratories $ABT Shares Purchased by Advyzon Investment Management LLC

Advyzon Investment Management LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 33.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,732 shares of the healthcare product maker’s stock after purchasing an additional 1,185 shares during the quarter. Advyzon Investment Management LLC’s holdings in Abbott Laboratories were worth $644,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories in the 1st quarter valued at $27,000. CWM LLC increased its stake in shares of Abbott Laboratories by 5.0% in the 1st quarter. CWM LLC now owns 263,215 shares of the healthcare product maker’s stock worth $34,915,000 after acquiring an additional 12,647 shares during the last quarter. Marks Group Wealth Management Inc raised its holdings in shares of Abbott Laboratories by 3.5% during the 1st quarter. Marks Group Wealth Management Inc now owns 8,104 shares of the healthcare product maker’s stock worth $1,075,000 after acquiring an additional 272 shares during the period. Finally, LRI Investments LLC boosted its position in shares of Abbott Laboratories by 9.8% during the 1st quarter. LRI Investments LLC now owns 3,684 shares of the healthcare product maker’s stock valued at $489,000 after acquiring an additional 330 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $125.88 on Tuesday. The firm has a 50 day moving average of $130.65 and a two-hundred day moving average of $131.39. The stock has a market capitalization of $218.89 billion, a PE ratio of 15.77, a P/E/G ratio of 2.36 and a beta of 0.68. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. The business had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The company’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. The Goldman Sachs Group raised their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Raymond James Financial upped their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. Finally, Morgan Stanley upped their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.